ONCOMATRYXONCOMATRYX
ONCOMATRYX

ONCOMATRYX

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

2009Active36

About

ONCOMATRYX is a Spanish biopharmaceutical company focused on developing innovative cancer therapies. They specialize in Quantum ADCs (Antibody-Drug Conjugates) designed to target the tumor microenvironment. The company has recently secured significant funding to advance the clinical development of its novel drug candidates.

Technology stack

detected 2026-06-14
Est. monthly stack spend~$590/mo
EmailMicrosoft 365
Hosting
self_managed
Stack
jQueryWordPress
Compliance
GDPRCCPA
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does ONCOMATRYX do?

ONCOMATRYX is a Spanish biopharmaceutical company focused on developing innovative cancer therapies. They specialize in Quantum ADCs (Antibody-Drug Conjugates) designed to target the tumor microenvironment. The company has recently secured significant funding to advance the clinical development of its novel drug candidates.

How much funding has ONCOMATRYX raised?

ONCOMATRYX has raised a total of $107M in funding. The most recent round on record is Funding Round.

Where is ONCOMATRYX headquartered?

ONCOMATRYX is headquartered in Derio, Spain.

When was ONCOMATRYX founded?

ONCOMATRYX was founded in 2009.

What industry does ONCOMATRYX operate in?

ONCOMATRYX operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery, Clinical Trials.

How many employees does ONCOMATRYX have?

ONCOMATRYX has approximately 36 people on record.